Healthcare resource utilization and costs among patients with post-stroke spasticity before and after spasticity management including onabotulinumtoxina.
Journal
Journal of rehabilitation medicine
ISSN: 1651-2081
Titre abrégé: J Rehabil Med
Pays: Sweden
ID NLM: 101088169
Informations de publication
Date de publication:
30 Oct 2023
30 Oct 2023
Historique:
received:
14
03
2023
accepted:
26
09
2023
medline:
31
10
2023
pubmed:
30
10
2023
entrez:
30
10
2023
Statut:
epublish
Résumé
Real-world data regarding the impact of onabotulinumtoxinA on healthcare resource utilization and costs for post-stroke spasticity are scarce. To compare differences in 12-month healthcare resource utilization and costs before and after post-stroke spasticity management including onabotulinumtoxinA. This retrospective claims analysis of IBM MarketScan Commercial and Medicare Supplemental databases included adults with ≥ 1 onabotulinumtoxinA claim for post-stroke spasticity (1 January 2010 to 30 June 2018) and continuous enrolment for ≥ 12 months pre- and post-index (first onabotulinumtoxinA claim date). All-cause and spasticity-related healthcare resource utilization and costs were compared 12 months pre- and post-index (McNemar's χ2 test or paired t-test). A subgroup analysis assessed effect of stroke-to-index interval on costs. Among 735 patients, mean (standard deviation) stroke-date-to-index-date interval was 284.5 (198.8) days. Decreases were observed post-index for mean all-cause outpatient (62.9 vs 60.5; p ≤ 0.05) and emergency department visits (1.1 vs 0.8; p ≤ 0.0001), and hospital admissions (1.5 vs 0.4; p ≤ 0.0001). Increase in prescription fills (43.0 vs 53.7) was seen post-index. Post-index decreases in all-cause (-66%) and spasticity-related (-51%) costs were driven by reduced inpatient care costs. Findings were consistent regardless of stroke-date-to-index-date interval. Significant reductions in healthcare resource utilization and costs were observed after 1 year of post-stroke spasticity management including onabotulinumtoxinA. Long-term studies are needed to establish causality.
Sections du résumé
BACKGROUND
BACKGROUND
Real-world data regarding the impact of onabotulinumtoxinA on healthcare resource utilization and costs for post-stroke spasticity are scarce.
OBJECTIVE
OBJECTIVE
To compare differences in 12-month healthcare resource utilization and costs before and after post-stroke spasticity management including onabotulinumtoxinA.
METHODS
METHODS
This retrospective claims analysis of IBM MarketScan Commercial and Medicare Supplemental databases included adults with ≥ 1 onabotulinumtoxinA claim for post-stroke spasticity (1 January 2010 to 30 June 2018) and continuous enrolment for ≥ 12 months pre- and post-index (first onabotulinumtoxinA claim date). All-cause and spasticity-related healthcare resource utilization and costs were compared 12 months pre- and post-index (McNemar's χ2 test or paired t-test). A subgroup analysis assessed effect of stroke-to-index interval on costs.
RESULTS
RESULTS
Among 735 patients, mean (standard deviation) stroke-date-to-index-date interval was 284.5 (198.8) days. Decreases were observed post-index for mean all-cause outpatient (62.9 vs 60.5; p ≤ 0.05) and emergency department visits (1.1 vs 0.8; p ≤ 0.0001), and hospital admissions (1.5 vs 0.4; p ≤ 0.0001). Increase in prescription fills (43.0 vs 53.7) was seen post-index. Post-index decreases in all-cause (-66%) and spasticity-related (-51%) costs were driven by reduced inpatient care costs. Findings were consistent regardless of stroke-date-to-index-date interval.
CONCLUSION
CONCLUSIONS
Significant reductions in healthcare resource utilization and costs were observed after 1 year of post-stroke spasticity management including onabotulinumtoxinA. Long-term studies are needed to establish causality.
Identifiants
pubmed: 37902443
doi: 10.2340/jrm.v55.11626
pmc: PMC10715292
doi:
Substances chimiques
Botulinum Toxins, Type A
EC 3.4.24.69
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
jrm11626Références
J Neurol. 2010 Jul;257(7):1067-72
pubmed: 20140444
J Rehabil Med. 2009 Jan;41(1):13-25
pubmed: 19197564
PM R. 2020 Nov;12(11):1120-1133
pubmed: 31953896
J Natl Med Assoc. 2018 Dec;110(6):547-552
pubmed: 30129501
J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):217-21
pubmed: 10896696
Neurology. 2016 May 10;86(19):1818-26
pubmed: 27164716
Eur Stroke J. 2018 Sep;3(3):237-245
pubmed: 31008354
J Cent Nerv Syst Dis. 2021 Sep 20;13:11795735211036576
pubmed: 34566442
Neurology. 2013 Jan 15;80(3 Suppl 2):S13-9
pubmed: 23319481
Expert Rev Neurother. 2022 Jan;22(1):27-42
pubmed: 34933648
Ann Phys Rehabil Med. 2019 Nov;62(6):403-408
pubmed: 29604351
Eur J Neurol. 2008 Jun;15(6):533-9
pubmed: 18355307
J Rehabil Med. 2005 Jul;37(4):252-7
pubmed: 16024483
Am J Manag Care. 2010 Jul;16(7):525-33
pubmed: 20645668
Clin Interv Aging. 2015 Nov 06;10:1793-802
pubmed: 26609225
J Neural Transm (Vienna). 2008;115(4):617-23
pubmed: 18322637
Stroke. 2010 Sep;41(9):2016-20
pubmed: 20705930
PLoS One. 2017 Apr 6;12(4):e0174861
pubmed: 28384164
Disabil Rehabil. 2005 Jan 7-21;27(1-2):2-6
pubmed: 15799140
Eur J Neurol. 2013 May;20(5):773-80
pubmed: 23278954
J Cardiovasc Nurs. 2020 Jan/Feb;35(1):86-94
pubmed: 31804249
Stroke. 2011 May;42(5):1371-9
pubmed: 21415398
Curr Med Res Opin. 2018 Jul;34(7):1317-1324
pubmed: 29490512
N Engl J Med. 2002 Aug 8;347(6):395-400
pubmed: 12167681
Stroke. 2010 Feb;41(2):319-24
pubmed: 20044535